Fredun Pharmaceuticals Limited (BOM:539730)
India · Delayed Price · Currency is INR | Market Cap | 13.96B +302.2% |
| Revenue (ttm) | 6.35B +40.0% |
| Net Income | 326.21M +65.3% |
| EPS | 61.23 +44.0% |
| Shares Out | 5.51M |
| PE Ratio | 41.37 |
| Forward PE | n/a |
| Dividend | 0.70 (0.03%) |
| Ex-Dividend Date | Jun 23, 2026 |
| Volume | 24,781 |
| Open | 2,320.00 |
| Previous Close | 2,314.65 |
| Day's Range | 2,320.00 - 2,565.00 |
| 52-Week Range | 791.00 - 2,620.00 |
| Beta | 0.69 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 25, 2026 |
About Fredun Pharmaceuticals
Fredun Pharmaceuticals Limited manufactures and sells pharmaceutical formulations, dietary/herbal supplements, nutraceuticals, and other healthcare products in India, Africa, Southeast Asia, Commonwealth of Independent States countries, MENA region, and Latin America. The company offers allopathic formulations, including analgesics/NSAID, antacid/antiulcer, anthelmintic, anti-bacterial, anti-diabetic, anti-inflammatory, anti-malarial, anti-obesity, antacid, anthelmintic, antibacterial, analgesics, anti-diabetic, anti-inflammatory, anti-malarial... [Read more]
Financial Performance
In fiscal year 2026, Fredun Pharmaceuticals's revenue was 6.35 billion, an increase of 40.03% compared to the previous year's 4.54 billion. Earnings were 326.21 million, an increase of 65.26%.
Financial StatementsNews
Fredun Pharmaceuticals Quarterly report: Q4 2026
Fredun Pharmaceuticals has published its Q4 2026 quarterly earnings report on May 25, 2026.
Fredun Pharmaceuticals Annual report: Q4 2026
Fredun Pharmaceuticals has published its Q4 2026 annual report on May 25, 2026.
Fredun Pharmaceuticals Transcript: Q3 25/26
Q3 and nine-month FY26 saw strong revenue and profit growth, with significant margin expansion. Legacy business grew 15–20% YoY, while New Age segments like pet care and mobility are scaling rapidly. No immediate funding needs are anticipated, and margins are expected to improve as new brands mature.
Fredun Pharmaceuticals Quarterly report: Q3 2026
Fredun Pharmaceuticals has published its Q3 2026 quarterly earnings report on February 9, 2026.
Fredun Pharmaceuticals Transcript: Q2 25/26
Strong Q2 and H1 FY26 results with double-digit revenue and profit growth, driven by expansion in pet care, nutraceuticals, and mobility. Strategic acquisitions and manufacturing expansion support long-term growth, with positive cash flow and robust guidance for the coming years.
Fredun Pharmaceuticals Quarterly report: Q2 2026
Fredun Pharmaceuticals has published its Q2 2026 quarterly earnings report on November 11, 2025.
Fredun Pharmaceuticals Transcript: Q1 25/26
Q1 FY 2026 saw revenue rise 52% and net profit 64% year-on-year, driven by strong branded generics and pet care growth. The company targets to double revenue and PAT in 3-4 years, with new age business expected to contribute over half of future revenue.
Fredun Pharmaceuticals Quarterly report: Q1 2026
Fredun Pharmaceuticals has published its Q1 2026 quarterly earnings report on August 1, 2025.
Fredun Pharmaceuticals stock jumps 3% after company set to launch advanced functional foods plant
Fredun Pharmaceuticals Limited saw a 3% jump in its stock price following the announcement of its new cutting-edge functional foods manufacturing facility. Located in Palghar, Maharashtra, this state-...